Akari Therapeutics plc has established a strategic research collaboration with Whitehawk Therapeutics Inc. to conduct preclinical studies evaluating Akari’s proprietary PH1 spliceosome-modulating payload technology in combination with Whitehawk’s topoisomerase I inhibitor antibody-drug conjugate platform.